First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm

被引:15
作者
Arver, B
Borg, Å
Lindblom, A
机构
[1] Karolinska Inst, Dept Mol Med, Clin Genet Unit, S-17176 Stockholm, Sweden
[2] Univ Lund Hosp, Dept Oncol, Lund, Sweden
来源
GENETIC TESTING | 2001年 / 5卷 / 01期
关键词
D O I
10.1089/109065701750168581
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The aim of the study was to optimize the criteria for the BRCA1 and BRCA2 gene testing and to improve oncogenetic counseling in the Stockholm region. Screening for inherited breast cancer genes is laborious and a majority of tested samples turn out to be negative. The frequencies of mutations in the BRCA1 and BRCA2 genes differ across populations. Between 1997 and 2000, 160 families with breast and/or ovarian cancer were counseled and screened for mutations in the two genes. Twenty-five BRCA1 and two BRCA2 disease-causing mutations were found. Various factors associated with the probability of finding a BRCA1 mutation in the families were estimated. Age of onset in different generations and other malignancies were also studied. Families from our region in which both breast and ovarian cancer occur were likely to carry a BRCA1 mutation (34%). In breast-only cancer families, mutations were found only in those with very early onset. All breast-only cancer families with a mutation had at least one case of onset before 36 years of age and a young median age of onset (< 43 years). Other malignancies than breast and ovarian cancers did not segregate in the BRCA1 families and surveillance for other malignancies is not needed, in general. Decreasing age of onset with successive generations was common and must be taken into account when surveillance options are considered.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 24 条
[1]  
Abeliovich D, 1997, AM J HUM GENET, V60, P505
[2]   BRCA1 screening in patients with a family history of breast or ovarian cancer [J].
Arver, B ;
Claro, A ;
Langerod, A ;
Borresen-Dale, AL ;
Lindblom, A .
GENETIC TESTING, 1999, 3 (02) :223-226
[3]   BRCA2 germline mutations in Swedish breast cancer families [J].
Chen, JD ;
Hedman, MZ ;
Arver, BW ;
Sigurdsson, S ;
Eyfjörd, JE ;
Lindblom, A .
EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 (02) :134-139
[4]   Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA [J].
Dorum, A ;
Hovig, E ;
Tropé, C ;
Inganas, M ;
Moller, P .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (05) :779-781
[5]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[6]   Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer [J].
FitzGerald, MG ;
MacDonald, DJ ;
Krainer, M ;
Hoover, I ;
ONeil, E ;
Unsal, H ;
SilvaArrieto, S ;
Finkelstein, DM ;
BeerRomero, P ;
Englert, C ;
Sgroi, DC ;
Smith, BL ;
Younger, JW ;
Garber, JE ;
Duda, RB ;
Mayzel, KA ;
Isselbacher, KJ ;
Friend, SH ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (03) :143-149
[7]   CONFIRMATION OF BRCA1 LAY ANALYSIS OF GERMLINE MUTATIONS LINKED TO BREAST AND OVARIAN-CANCER IN 10 FAMILIES [J].
FRIEDMAN, LS ;
OSTERMEYER, EA ;
SZABO, CI ;
DOWD, P ;
LYNCH, ED ;
ROWELL, SE ;
KING, MC .
NATURE GENETICS, 1994, 8 (04) :399-404
[8]  
Hakansson S, 1997, AM J HUM GENET, V60, P1068
[9]  
Johannesdottir G, 1996, CANCER RES, V56, P3663
[10]   Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus [J].
Kainu, T ;
Juo, SHH ;
Desper, R ;
Schäffer, AA ;
Gillanders, E ;
Rozenblum, E ;
Freas-Lutz, D ;
Weaver, D ;
Stephan, D ;
Bailey-Wilson, J ;
Kallioniemi, OP ;
Tirkkonen, M ;
Syrjäkoski, K ;
Kuukasjärvi, T ;
Koivisto, P ;
Karhu, R ;
Holli, K ;
Arason, A ;
Johannesdottir, G ;
Bergthorsson, JT ;
Johannsdottir, H ;
Egilsson, V ;
Barkardottir, RB ;
Johannsson, O ;
Haraldsson, K ;
Sandberg, T ;
Holmberg, E ;
Grönberg, H ;
Olsson, H ;
Borg, Å ;
Vehmanen, P ;
Eerola, H ;
Heikkilä, P ;
Pyrhönen, S ;
Nevanlinna, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (17) :9603-9608